SEC Comment Letter 0000000000-24-014218 to Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc.
Date: Dec. 23, 2024 · CIK: 0001662774 · Accession: 0000000000-24-014218
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283897
Letter
December 23, 2024 Dirk Thye, M.D. Chief Executive Officer and Chief Medical Officer Quince Therapeutics, Inc. 611 Gateway Boulevard, Suite 273 South San Francisco, CA 94080 Re:Quince Therapeutics, Inc. Registration Statement on Form S-3 Filed December 18, 2024 File No. 333-283897 Dear Dirk Thye M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gordon K. Ho, Esq.
Show Raw Text
December 23, 2024
Dirk Thye, M.D.
Chief Executive Officer and Chief Medical Officer
Quince Therapeutics, Inc.
611 Gateway Boulevard, Suite 273
South San Francisco, CA 94080
Re:Quince Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 18, 2024
File No. 333-283897
Dear Dirk Thye M.D.:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gordon K. Ho, Esq.